Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis

World Journal of Gastroenterology

Volumn 23, Issue 11, 2017, Pages 2023-2028

  Jain, Animesh ^a   Lipson, Evan J ^b   Sharfman, William H ^b   Brant, Steven R ^b   Lazarev, Mark G ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colitis; Colonic ulcer; Corticosteroid; Enterocolitis; Infliximab; Ipilimumab; Melanoma

Indexed keywords

INFLIXIMAB; IPILIMUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLONOSCOPY; CONTROLLED STUDY; CRYPT ABSCESS; CRYPT APOPTOSIS; CRYPTITIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ENTEROCOLITIS; ENTEROPATHY; ERYTHEMA; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; INTESTINE ULCER; MALE; MENTAL INSTABILITY; METASTATIC MELANOMA; MIDDLE AGED; NAUSEA; PREDICTION; REFRACTORY COURSE; RETROSPECTIVE STUDY; SIGMOIDOSCOPY; SINGLE DRUG DOSE; TREATMENT OUTCOME; VAGINA CANDIDIASIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLONIC DISEASES; DRUG RESISTANCE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; SKIN NEOPLASMS; ULCER;

ADMINISTRATION, INTRAVENOUS; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLONIC DISEASES; COLONOSCOPY; CTLA-4 ANTIGEN; DIARRHEA; DRUG RESISTANCE; ENTEROCOLITIS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; MALE; MELANOMA; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; ULCER;

EID: 85015726665     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i11.2023     Document Type: Article

References (13)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 [PMID: 20525992 DOI: 10.1056/NEJMoa1003466]
2. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526 [PMID: 21639810 DOI: 10.1056/NEJMoa1104621]
3. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbé C. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, doseranging study. Lancet Oncol 2010; 11: 155-164 [PMID: 20004617 DOI: 10.1016/S1470-2045(09)70334-1]
4. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter singlearm phase II study. Ann Oncol 2010; 21: 1712-1717 [PMID: 20147741 DOI: 10.1093/annonc/mdq013]
5. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-5598 [PMID: 19671877 DOI: 10.1158/1078-0432. CCR-09-1024]
6. Weber JS, Kähler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697 [PMID: 22614989 DOI: 10.1200/JCO.2012.41.6750]
7. Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, Steinbach G, McDonald GB. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 2010; 55: 1396-1405 [PMID: 19507029 DOI: 10.1007/s10620-009-0839-8]
8. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009; 24: 321-325 [PMID: 19538054 DOI: 10.1089/cbr.2008.0607]
9. Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54: 2538-2540 [PMID: 19104936 DOI: 10.1007/s10620-008-0641-z]
10. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D'Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193-3198 [PMID: 26282644 DOI: 10.1200/JCO.2015.60.8448]
11. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24: 2283-2289 [PMID: 16710025 DOI: 10.1200/JCO.2005.04.5716]
12. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyteassociated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-1016 [PMID: 16283570 DOI: 10.1245/ASO.2005.03.536]
13. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, Targan SR, Wang HL. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10: 11 [PMID: 21090563]